| Product Code: ETC9961665 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Cannabis Pharmaceutical Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Cannabis Pharmaceutical Market - Industry Life Cycle |
3.4 United States (US) Cannabis Pharmaceutical Market - Porter's Five Forces |
3.5 United States (US) Cannabis Pharmaceutical Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 United States (US) Cannabis Pharmaceutical Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.7 United States (US) Cannabis Pharmaceutical Market Revenues & Volume Share, By Compound Type, 2021 & 2031F |
3.8 United States (US) Cannabis Pharmaceutical Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.9 United States (US) Cannabis Pharmaceutical Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.10 United States (US) Cannabis Pharmaceutical Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United States (US) Cannabis Pharmaceutical Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing acceptance and legalization of medical cannabis in the US |
4.2.2 Growing awareness about the potential therapeutic benefits of cannabis-based pharmaceuticals |
4.2.3 Rising demand for alternative treatment options for chronic conditions |
4.3 Market Restraints |
4.3.1 Stringent regulatory environment and varying state laws regarding cannabis usage |
4.3.2 Limited availability of clinical evidence supporting the efficacy and safety of cannabis pharmaceuticals |
4.3.3 Concerns about potential misuse and abuse of cannabis products |
5 United States (US) Cannabis Pharmaceutical Market Trends |
6 United States (US) Cannabis Pharmaceutical Market, By Types |
6.1 United States (US) Cannabis Pharmaceutical Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Product Type, 2021- 2031F |
6.1.3 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Capsules, 2021- 2031F |
6.1.4 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Concentrates, 2021- 2031F |
6.1.5 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Edibles, 2021- 2031F |
6.2 United States (US) Cannabis Pharmaceutical Market, By Drugs |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Epidiolex, 2021- 2031F |
6.2.3 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Marinol, 2021- 2031F |
6.2.4 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Cesamet, 2021- 2031F |
6.2.5 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Sativex, 2021- 2031F |
6.3 United States (US) Cannabis Pharmaceutical Market, By Compound Type |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Tetrahydrocannabinol (THC), 2021- 2031F |
6.3.3 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Cannabidiol (CBD), 2021- 2031F |
6.3.4 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Balanced THC & CBD, 2021- 2031F |
6.4 United States (US) Cannabis Pharmaceutical Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Inflammation, 2021- 2031F |
6.4.3 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Chronic Pain, 2021- 2031F |
6.4.4 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Epilepsy, 2021- 2031F |
6.4.5 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Sleep Disorders, 2021- 2031F |
6.4.6 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Anorexia, 2021- 2031F |
6.4.7 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Schizophrenia, 2021- 2031F |
6.5 United States (US) Cannabis Pharmaceutical Market, By End-Users |
6.5.1 Overview and Analysis |
6.5.2 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Clinic, 2021- 2031F |
6.5.3 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Hospital, 2021- 2031F |
6.6 United States (US) Cannabis Pharmaceutical Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.6.4 United States (US) Cannabis Pharmaceutical Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
7 United States (US) Cannabis Pharmaceutical Market Import-Export Trade Statistics |
7.1 United States (US) Cannabis Pharmaceutical Market Export to Major Countries |
7.2 United States (US) Cannabis Pharmaceutical Market Imports from Major Countries |
8 United States (US) Cannabis Pharmaceutical Market Key Performance Indicators |
8.1 Number of states with legalized medical cannabis programs |
8.2 Research and development investment in cannabis pharmaceuticals |
8.3 Patient enrollment in clinical trials for cannabis-based medications |
9 United States (US) Cannabis Pharmaceutical Market - Opportunity Assessment |
9.1 United States (US) Cannabis Pharmaceutical Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 United States (US) Cannabis Pharmaceutical Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.3 United States (US) Cannabis Pharmaceutical Market Opportunity Assessment, By Compound Type, 2021 & 2031F |
9.4 United States (US) Cannabis Pharmaceutical Market Opportunity Assessment, By Application, 2021 & 2031F |
9.5 United States (US) Cannabis Pharmaceutical Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.6 United States (US) Cannabis Pharmaceutical Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United States (US) Cannabis Pharmaceutical Market - Competitive Landscape |
10.1 United States (US) Cannabis Pharmaceutical Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Cannabis Pharmaceutical Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here